Fonseca Biosciences Secures Exclusive US Rights to XTORO® (finafloxacin otic suspension) 0.3% to Treat Swimmer’s Ear
December 11, 2024
XTORO is a New Chemical Entity that is FDA approved for the treatment of acute otitis externa, commonly known as “swimmer’s ear”, caused by susceptible strains of Pseudomonas aeruginosa and…
Read More